This drug may cause blurred vision, dizziness, and somnolence, if affected, do not drive or operate machinery.
Monitor for signs and symptoms of suicide ideation; rash; frequency and duration of seizures.
Increased plasma concentrations with valproate. May decrease the effect of oral contraceptives. May increase plasma levels of phenytoin and phenobarbital. May decrease plasma levels of carbamazepine and lamotrigine.
Food increases absorption.
Description: Rufinamide modulates the activity of sodium channels through prolongation of their inactive state, thereby limiting the repetitive firing of sodium-dependent action potentials mediating anticonvulsant effects. Pharmacokinetics: Absorption: Slowly and extensively absorbed from the GI tract. Bioavailability: ≥85%; increased with food. Time to peak plasma concentration: 4-6 hours. Distribution: Evenly distributed between erythrocytes and plasma. Volume of distribution: Approx 50 L. Plasma protein binding: 34%, mainly to albumin. Metabolism: Extensively metabolised via carboxylesterase-mediated hydrolysis of the carboxylamide group to inactive acid derivative CGP 47292. Excretion: Via urine (85%, approx 66% as CGP 47292, 2% as unchanged drug). Elimination half-life: Approx 6-10 hours.
N03AF03 - rufinamide ; Belongs to the class of carboximide derivatives antiepileptic. Used in the management of epilepsy.
Anon. Rufinamide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/02/2018.Banzel Tablet, Film Coated; Banzel Suspension (Eisai Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/02/2018.Buckingham R (ed). Rufinamide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/02/2018.Joint Formulary Committee. Rufinamide. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/02/2018.McEvoy GK, Snow EK, Miller J et al (eds). Rufinamide. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 08/02/2018.